Progression of Disease Within 24 Months (POD24) Based Prognostic Signature: A New Method for Personalized Risk Assessment in Patients with Mantle Cell Lymphoma

Mantle cell lymphoma (MCL) exhibits significant biological and clinical heterogeneity, necessitating a refined prognostic model. According to the drawback of the models existed which are not truly define the complexity of the disease, we used the clinical and molecular data from nine medical centers of China to validate the predictive utility in progression of disease within 24 months (POD24), and also establish a novel prognostic risk model to predict the survival outcome of MCL patients. POD24 occurred in 37.7% of evaluable patients, with median over survival was 21 months (vs 122 months for those without POD24, P < 0.0001). The POD24-based risk model had the highest sensitivity to predict to predict survival with the most satisfying AUC value for risk score (AUC = 0.869). In conclusion, we confirm the obviously predictive performance of POD24 and established a novel risk model combined POD24 and clinical factors. Our new prognostic model might be helpful to effectively classify MCL patients with high-risk groups in terms of survival rate, which may help select high-risk MCL patients for more intensive treatment at time of relapse.